Study #2018-0902
Hyperpolarized Pyruvate Imaging of Glioma: Imaging-Pathological Correlation
MD Anderson Study Status
Enrolling
Treatment Agent
Hyperpolarized Carbon C 13 Pyruvate
Description
This trial studies how an imaging agent, hyperpolarized carbon C 13 pyruvate, works in diagnosing glioma in patients with brain tumors. Giving hyperpolarized carbon C 13 pyruvate before an advanced imaging technique called a magnetic resonance spectroscopic imaging (MRSI) scan may help researchers better diagnose glioma in patients with brain tumors.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Primary Brain Neoplasm
Study phase:
Phase I
Physician name:
Dawid Schellingerhout
Department:
Diagnostic Radiology
For general questions about clinical trials:
1-877-695-0709
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.